The systemic treatment of uterine leiomyosarcomas: A systematic review. No news is good news?

Abstract

BACKGROUND:

Uterine leiomyosarcomas are rare malignant mesenchymal tumors. The systemic treatment of these tumors includes chemotherapy and radiotherapy. However, there are still a lot of unanswered questions regarding the ideal therapeutic approach.

METHODS:

We have conducted a systematic review of the treatment strategies of uterine leiomyosarcomas for the last ten years.

RESULTS:

Adjuvant chemotherapy is still a matter of dilemma. Doxorubicin based chemotherapy or the combination of Gemcitabine-Docetaxel are the regimens of choice for the first line setting. Beyond the first line, there are several options;, including chemotherapy, targeted therapy, and recently efforts of introducing immunotherapy to the therapeutic armamentarium of clinicians treating uterine leiomyosarcomas.

CONCLUSIONS:

Despite the efforts of the clinicians dealing with uterine leiomyosarcomas, the optimal therapeutic algorithm is yet to be described.

• Authors: Anastasios Kyriazoglou, Michalis Liontos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou
• Journal: Medicine (Medicine (Baltimore)) Vol. 100 Issue 13 Pg. e25309 (Apr 02 2021) ISSN: 1536-5964 [Electronic] United States
• PMID: 33787622 (Publication Type: Journal Article, Systematic Review)
• Copyright: Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Chemical References

• Deoxycytidine
• Doxorubicin
• Gemcitabine

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chemotherapy, Adjuvant (methods)
• Deoxycytidine (analogs & derivatives, therapeutic use)
• Doxorubicin (therapeutic use)
• Female
• Humans
• Immunotherapy (methods)
• Leiomyosarcoma (surgery)
• Molecular Targeted Therapy (methods)
• Treatment Outcome
• Uterine Neoplasms (surgery)
• Gemcitabine